Pfizer supplies EU another 1.8 billion vaccines

The European Union can count on a further 1.8 billion coronavaccines from PFIZER/BionTech over the next two years. The contract with the vaccine manufacturer has been concluded, says President Ursula von der Leyen of the European Commission.

The committee announced a month ago that a new order was under way. Brussels has already ordered billions of doses from several vaccine makers, more than enough to vaccinate all around 450 million EU citizens. But it may prove necessary to repeat the prick or virus mutants appear that require an additional dose. The committee wants to be prepared for this.

Pfizer will deliver another 900 million doses from the end of the year, and the EU will be entitled to another amount, according to Von der Leyen. In principle, vaccines purchased by the EU are distributed fairly among the Member States. This would allow the Netherlands to claim at least 70 million doses under the new contract.

Preparing

the inoculation โ€œprogresses wellโ€, says Von der Leyen. That is why the time has come โ€œto prepare for the next phase of our approach: to refresh, to absorb virus variants that are resistant to current vaccines and to enable children and teenagers to be vaccinated.โ€

The major task underlines that the EU is increasingly committed to the Pfizer vaccine and other similar products. Their new so-called MRNA technology would have proved itself, while vaccines with different effects such as AstraZeneca have many problems.

The Netherlands has its reservations about this. According to demissionary coronaminister Hugo de Jonge, it is better to continue spreading the chances and thus also to order other vaccines.

That‘s what’s going to happen, announces Von der Leyen. โ€œOther contracts and other vaccine technologies will follow.โ€

The EU and the manufacturer keep secret what the Union pays for the vaccine. The Pfizer vaccine is one of the more expensive coronav vaccines. That is why some EU countries have previously renounced the Pfizer vaccines that Brussels had negotiated for them. They came back from that because PFIZER/BionTech, unlike other vaccine manufacturers, does manage to deliver on time.

The means of Pfizer is of state-of-the-art, not previously used cut. The MRNA vaccines do not induce an immune response using (part of) the virus, but instruct body cells to produce proteins similar to those of the virus. In response to these proteins, people start producing antibodies, which then attack the virus when it penetrates.